Physician profile
Karen L Stanek
NPI 1225017411
$18,982.85
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,538 · 2020: $2,455 · 2021: $962 · 2022: $262 · 2023: $1,026 · 2024: $9,740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,550 · Travel and Lodging: $1,429 · Food and Beverage: $729 · Education: $58.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,550.00 |
| Travel and Lodging | $1,428.90 |
| Food and Beverage | $728.87 |
| Education | $58.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $16,711.31 | 2019-2024 | Dysport |
| Allergan, INC. | $514.73 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $262.81 | 2019-2021 | |
| Lilly USA, LLC | $250.03 | 2019-2022 | |
| Merz North America, INC. | $164.68 | 2019-2020 | |
| Merz Pharmaceuticals, LLC | $156.38 | 2021-2022 | |
| Amgen INC. | $154.41 | 2019-2021 | |
| Smith+Nephew, INC. | $99.94 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $81.77 | 2020-2021 | |
| Saol Therapeutics INC. | $79.46 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $56.45 | 2019-2021 | |
| Abbvie INC. | $56.19 | 2021-2022 | |
| Pfizer INC. | $53.71 | 2019-2020 | |
| Piramal Critical Care | $45.66 | 2020 | |
| Medtronic, INC. | $43.12 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $42.20 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.09 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.43 | 2022 | |
| Avanir Pharmaceuticals, INC. | $25.99 | 2019 | |
| Impel Pharmaceuticals INC. | $23.39 | 2022 | |
| Nevro Corp. | $21.77 | 2019 | |
| Xeris Pharmaceuticals, INC. | $20.42 | 2021 | |
| Medtronic USA, INC. | $17.97 | 2020 | |
| Strongbridge US INC. | $15.90 | 2020 | |
| Eisai INC. | $13.30 | 2021 | |
| Neurocrine Biosciences, INC. | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Stanek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.